Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE initiative

Pharmacotherapy

Volumn 29, Issue 6, 2009, Pages 631-638

  Spinler, Sarah A ^a   Ou, Fang Shu ^b   Roe, Matthew T ^b   Gibler, W Brian ^c   Ohman, Magnus ^b   Pollack, Charles V ^d   Alexander, Karen P ^b   Peterson, Eric D ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d PENNSYLVANIA HOSPITAL   (United States)

Author keywords

ACS; Acute coronary syndromes; Anticoagulation; Enoxaparin; Non ST segment elevation; NSTE; Obesity

Indexed keywords

ENOXAPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; RECOMMENDED DRUG DOSE; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; BODY WEIGHT; COHORT STUDIES; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; UNITED STATES;

EID: 66849115485     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.6.631     Document Type: Article

References (20)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157.
2. Oliveira GB, Avezum A, Anderson FA Jr, et al. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based stratification. Am Heart J 2007;153:493-499 (Pubitemid 46442805)
3. sanofi aventis. Lovenox (enoxaparin sodium injection) package insert. Bridgewater, NJ; 2005.
4. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-3116 (Pubitemid 43016802)
5. LaPointe NM, Chen AY, Alexander KP, et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2007;167:1539-1544 (Pubitemid 47124185)
6. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-318
7. Macie C, Forbes L, Foster GA, Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004;125:1616-1621 (Pubitemid 38648388)
8. Spinler SA, Dobesh P. Dose capping is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest 2005;127:2288-2290 (Pubitemid 46260134)
9. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202. (Pubitemid 32113321)
10. Barba R, Marco J, Martín-Alvarez H, et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005;3:856-862 (Pubitemid 41632810)
11. Spinler SA. The skinny on treatment of venous thromboembolism in obesity. J Thrombos Haemost 2005;3:854-855 (Pubitemid 41632809)
12. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41. (Pubitemid 36851297)
13. Davidson BL, Büller HR, Decousus H, et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007;5:1191-1194 (Pubitemid 46902121)
14. Hoekstra JW, Pollack CV Jr, Roe MT, et al. Improving the care of patients with non-ST-segment elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 2002;9:1146-1155 (Pubitemid 35291543)
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. World Health Organization. Obesity and overweight. Fact sheet no. 311, September 2006. Available from http://www.who.int/mediacentre/factsheets/fs311/ en/print.html. Accessed December 28, 2008.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
18. Moscucci M, Fox KAA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndrome: the global registry of acute coronary events (GRACE). Eur Heart J 2003;24:1815-1823. (Pubitemid 37280247)
19. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126 (3 suppl):S188-203. (Pubitemid 39297954)
20. George-Phillips KL, Bungard TJ. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Pharmacotherapy 2006;26:1479-1490 (Pubitemid 44521733)